Evidence map›Paper›PMID 25653965›Full record

ArticleJournal of clinical and diagnostic research : JCDR2014

Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization.

Ashutosh Kumar, Goru Bhawani, Neera Kumari, Kasturi Sn Murthy, Vinod Lalwani, Ch Narasimha Raju

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03767322 (Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03767322 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

TypeinterventionalSponsorInstituto Nacional de Cardiologia Ignacio ChavezRan2018 to 2019Enrolled558ConditionsContrast-induced Nephropathy, Contrast-induced Acute Kidney InjuryArmsAllopurinol, Febuxostat, Placebo
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Are There Modifiable Risk Factors to Improve AKI?BioMed research international · 2017
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ashutosh KumarAssistant Professor, Department of Cardiology, GSL Medical College and Hospital , Rajahmundry, India .
Goru BhawaniAssociate Professor, Department of Pharmacology, GSL Medical College & Hospital , Rajahmundry, India .
Neera KumariAssistant Professor, Department of Physiology, Sri Krishna Medical College , Muzzafarpur, India .
Kasturi Sn MurthyHead of the Department, Department of Pharmacolgy, GSL Medical College & Hospital , Rajahmundry, India .
Vinod LalwaniJunior Resident, Department of Cardiology, GSL Medical College Rajahmundry, India .
Ch Narasimha RajuJunior Resident, Department of Cardiology, GSL Medical College Rajahmundry, India .
GSL Medical College & General Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledObjectives : To evaluate the difference in the renal protective effects of allopurinol and n-acetyl cysteine along with saline hydration in patients of contrast induced nephropathy (CIN) post cardiac interventions.

backgroundCIN remains a common complication of cardiac procedures. Radio contrast agents can cause a reduction in renal function that may be related to oxidative stress underlining various patho- physiologies. Conflicting evidence suggests that administration of allopurinol, a xanthine oxidase inhibitor can prevent CIN. MATERIALS AND

methodsThis is a study of 500 patients undergoing angiography and coronary revascularisation in patients showing significant coronary block. The angiography positive patients (275) were prospectively randomised to different treatment protocol to study for their reno-protective effect. The patients received either of the three drugs saline hydration (SH, 1ml/kg/hr), n-acetylcysteine (SH+NAC, 600 mg bd) or Allopurinol (SH+ALLP, 300 mg/day) 12 hours before and after administration of radio contrast agent. Levels of serum creatinine and blood urea of the 275 patients recorded at 24 hour interval were noted post angioplasty over a course of 5 days in patients receiving either omnipaque (125) or visipaque (150) contrast media. All the 500 patients were also assessed for development of any kind of adverse drug effects/reactions with the two contrast media.

resultsCIN occurred in 56 of 500 the patients (10.6%) who underwent angiography and 49 of 275 patients (17.8%) who underwent angioplasty. In the omnipaque group CIN occurred in 16/40, 8/40, nil/45 in patients receiving SH, NAC plus SH and SH plus ALLP respectively. In the visipaque group CIN occurred in 15/50, 10/50, nil/50 in the three treatments groups respectively. Allopurinol maintained a consistent fall in the serum creatinine & blood urea levels from the baseline values from the end of the 1(st) day (p < .01 & .001) in both the category. Visipaque proved to be better dye than omnipaque with less adverse drug effects/ reactions.

conclusionProphylactic oral administration of allopurinol (300 mg/day) along with hydration is better than n-acetylcysteine and saline hydration alone for protection against CIN in patients undergoing coronary procedures.

Indexed as

AllopurinolContrast nephropathyOmnipaquePercutaneous coronary interventionsVisipaque

Identifiers

PMID25653965
PMCPMC4316271
OpenAlexW2015308540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.